Cellular protein trafficking defects may contribute to neurodevelopmental disorders in ways previously underappreciated by clinical researchers. The intricate dance of proteins moving from cellular manufacturing sites to their functional destinations can determine whether neurons fire properly or fail catastrophically. A heterozygous variant in the KCNC1 gene (p.Ser474Cys) has been identified in a patient with classical Rett syndrome, revealing how a single amino acid substitution disrupts the normal trafficking pathway of Kv3.1 potassium channels from the endoplasmic reticulum to the Golgi apparatus. This trafficking disruption prevents the channels from reaching neuronal membranes where they enable high-frequency neuronal firing patterns essential for normal brain function. The finding expands understanding of Rett syndrome beyond the well-characterized MECP2 mutations that account for most cases. While MECP2 variants affect gene regulation, this KCNC1 variant operates through a different mechanism - protein misfolding and cellular trafficking failure. This mechanistic diversity suggests that multiple pathways can converge on similar clinical presentations in neurodevelopmental disorders. The research has broader implications for understanding ion channel diseases, or channelopathies, where cellular localization defects may be as important as functional channel defects. However, this represents a single case study, and the clinical penetrance and frequency of KCNC1 variants in Rett syndrome remain unclear. The trafficking defect mechanism also raises questions about whether pharmacological chaperones or other interventions might restore normal protein folding and transport, potentially offering therapeutic targets distinct from current gene therapy approaches focused on MECP2 replacement.